Who's Who

Magali Olivier

Scientist

Molecular Mechanisms and Biomarkers Group


Specialty:

Molecular biology and epidemiology of cancer, biological databases

Academic Degrees

YearDegreeMajorInstitutionTownCountry
1998PhDMolecular and cellular biology of cancerUniversity of MontpellierMontpellierFrance
1993DEABiochemistry & HealthUniversity of MontpellierMontpellierFrance
1992MaitriseBiochemistryUniversity of Nice Sofia-AntipolisNiceFrance
1991LicenceBiochemistryUniversity of Nice Sofia-AntipolisNiceFrance
1990DEUGBiologyUniversity of Nice Sofia-AntipolisNiceFrance


Current Research Projects

  • Mutational signatures of carcinogens

  • IARC TP53 database (p53.iarc.fr)

  • Functional genomics of breast cancer

  • Biomarkers in lung cancer


Selected Publications

Olivier M, Weninger A, Ardin M, Huskova H, Castells X, Vallee MP, McKay J, Nedelko T, Muehlbauer KR, Marusawa H, Alexander J, Hazelwood L, Byrnes G, Hollstein M, Zavadil J. (2014) Modelling mutational landscapes of human cancers in vitro. Sci Rep; 4:4482

Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M and Pierre-Jean Souquet. (2014) Non-Invasive Diagnosis of Actionable Mutations by Deep-Sequencing of Circulating-free DNA in Lung Cancer from Never-Smokers; A proof-of-concept study from BioCAST / IFCT-1002. Clin Cancer Res: 20:4613-24

Hollstein M, Moriya M, Grollman AP, Olivier M. (2013) Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. Mutat Res; 753(1):41-9

Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K, Quinaux E, Buyse M, Dolci MS, De Azambuja E, Hainaut P, Dell'Orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Di Leo A, and Olivier M. (2012) Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res; 14(3):R70

Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M. (2011) p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines. Int J Cancer; 128 (8):1813-21

Scientific Societies Membership

European Association for Cancer Research
Gene/Disease Specific Database Advisory Council of the Human Variome Project

Prizes, Honours

Exchange Visit Grant in Frontiers of Functional Genomics, ESF, 2011
Research Fellowship, Fondation pour la Recherche MĂ©dicale, 1997
Research fellowship, French Government, 1994-1996